FDA 483 - Hikma Pharmaceuticals USA Inc. - November 03, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Hikma Pharmaceuticals USA Inc., a human sterile drug manufacturer in Cherry Hill, NJ, received an FDA Form 483 with five observations. The firm demonstrated significant deficiencies in component identity testing, failed to thoroughly investigate unexplained discrepancies related to stability and dissolution, and exhibited poor equipment cleaning and maintenance. Additionally, the company did not submit Field Alert Reports in a timely manner and lacked proper identification for laboratory samples, indicating systemic quality control and compliance issues.
ID · 0d798230-9ea1-4d9b-8d2e-ffbff634ff89